Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 285

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 285
---
 risk free rate of 5.4% to 5.5%.Financial advisor warrantsThere were 297,029 warrants issued to our financial advisor, H.C. Wainwright & Co., LLC., related to merger transaction costs in connection with the reverse merger with Kintara. The warrants are considered “penny” warrants and are considered common stock outstanding as of December 31, 2024 (see note 4). The accounting for the warrants is determined to have zero net effect on total equity as of December 31, 2024. The fair value associated with the warrants was determined using Black-Sholes pricing model using the terms of the agreement and the following assumptions expected term of approximately 2.4 years, dividend yield of 0.0%, volatility of 120.4% and a risk free rate of 4.15% resulting in an estimated valuation of approximately $1,600,000.Warrants exercisedThere were 641,850 warrants that were exercised in August and September 2024 and 4,730 warrants that were exercised in December 2024 with proceeds in the amount of $1,944,765.  All outstanding warrants entitled the holder thereof to purchase one shares of Company common stock. 

Note 13—Stock option plansStock optionsThe Company uses the Black-Scholes option pricing model to estimate the fair value of stock-based awards on the date of grant. The assumptions employed in the calculation of the fair value of share-based compensation expense were calculated as follows for all periods presented: 

        2024

        2023

        Common stock fair value

        $
        4.76

        $
        3.69

        Risk free interest rate

        4.10% - 4.35%

        4.05% - 4.89%

        Expected dividend yield

        0%

        0%

        Expected term

        6.0 years

        4.9 years

        Expected stock volatility

        100.1% - 103.0%

        91.9% - 99.7%

       Below is a summary of stock option activity for the year ending December 31, 2024: 

        Weighted

        Weighted

        Number

        Average

        Average

        of options

        Exercise Price

        Contractual Life

        Outstanding at December 31, 2023
         
        2,781,064